The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

Bavarian's JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and ...

The first 300 doses were administered on Tuesday near the border with the Democratic Republic of Congo, a spokesperson for ...

MVA-BN is approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA. This is the second EMA approval of an MVA-BN-based vaccine for a younger ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

Gavi, the Vaccine Alliance, will purchase 500,000 doses of MVA-BN, the Bavarian Nordic Mpox vaccine, as part of an ...

The UN Children’s Fund, UNICEF, issued an urgent appeal on Friday for nearly $59 million to support efforts to halt the rapid ...

Health Minister of Indian state of Kerala, Veena George, said on Thursday that genome sequencing will be conducted to ...

Congo's South Kivu province is at the epicenter of the world’s latest mpox outbreak, in what the World Health Organization ...

Rwanda has launched the first mpox vaccination campaign in Africa, marking a significant step in the continent's fight ...